Sarepta Therapeutics Inc (SRPT)

Debt-to-equity ratio

Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Long-term debt US$ in thousands 1,132,520 1,544,290 1,096,880 992,493 681,900
Total stockholders’ equity US$ in thousands 859,337 384,950 928,009 761,759 818,187
Debt-to-equity ratio 1.32 4.01 1.18 1.30 0.83

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $1,132,520K ÷ $859,337K
= 1.32

The debt-to-equity ratio for Sarepta Therapeutics Inc has fluctuated over the past five years. In 2019, the ratio was 0.83, indicating that the company had a lower level of debt relative to its equity. However, this ratio increased to 1.30 in 2020, suggesting a slight rise in debt compared to equity. Subsequently, in 2021, the ratio decreased to 1.18, indicating a lower level of debt relative to equity compared to the previous year.

The biggest change occurred in 2022 where the debt-to-equity ratio significantly increased to 4.01, suggesting a substantial rise in debt relative to equity, which may indicate increased financial leverage and potential risk. However, in 2023, the ratio decreased to 1.32, showing a reduction in debt compared to equity from the previous year.

Overall, the trend in the debt-to-equity ratio for Sarepta Therapeutics Inc reflects varying levels of debt and equity financing over the years, implying fluctuations in the company's capital structure and financial risk profile. More detailed analysis and consideration of other financial metrics would be necessary to fully assess the implications of these changes for the company's financial health and performance.